The Royal enters into an exclusive agreement with Covance to collaborate on early clinical research
The Royal Liverpool and Broadgreen University Hospitals NHS Trust has entered into a five year exclusive agreement with a major American drug development company to work together on early clinical trials on behalf of biotechnology and pharmaceutical companies.
Covance Inc is a leader in clinical development services and has been conducting Phase I studies (i.e. studies where new drugs are being administered to humans for the first time) across its network of clinics for more than 35 years, including its clinical research unit in Leeds. The Trust also has a respected and demonstrated commitment to clinical research and specialised patient care services.
The agreement between the two will focus on early phase trials using the clinical research unit at the Royal Liverpool University Hospital.
Professional Robert Sutton, director of Research and Development at the Trust, said: “This is an extremely exciting collaboration with Covance and represents an industry-leading relationship in the world of clinical research.
“We have a successful track record in the field of experimental medicine and are unique in the UK in our investment in clinical pharmacology along with our position in the position in the local health and life science industry. We have the ability to work with new technologies to enhance the effectiveness and safety of new medicines for our patients.”
As part of its 2017 expansion plans, the Trust will look to expand the clinical research unit at the Royal which will help to establish it as a major bioscience hub. This increased focus on early clinical research will also give patients the opportunity to participate in early clinical research for potentially new breakthrough medicines.
Rob Aspbury, vice president and general manager, Global Clinical Pharmacology Services at Covance, said: “This is an innovative alliance which is designed to help make the drug development process more efficient and ultimately bring important drugs to market sooner to help patients in need.”